Clinical high-risk criteria of psychosis in 8–17-year-old community subjects and inpatients not suspected of developing psychosis

Table 4 Frequency of clinical high-risk criteria in the four diagnostic subsamples and the community sample (n = 539)

	ED (n = 97)	ADHD (n = 86)	AnxD and OCD (n = 94)	ASS (n = 29)	Community subjects (n = 233)	χ² test; Cramer’s V
APS syndrome: n (%)	4 (4.1)	0	3 (3.2)	0	5 (2.1)	χ² (4) = 4.632; P = 0.327, V = 0.093
Genetic risk and functional decline syndrome: n (%)	0	1 (1.2)	1 (1.1)	0	0	χ² (4) = 4.016; P = 0.404, V = 0.086
COGDIS: n (%)	4 (4.1)	2 (2.3)	4 (4.3)	0	4 (1.7)	χ² (4) = 3.427; P = 0.489, V = 0.080
COPER: n (%)	9 (9.3)	3 (3.5)	8 (8.5)	1 (3.4)	10 (4.3)	χ² (4) = 5.558; P = 0.235, V = 0.102
Any 1 of 5 CHR criteria: n (%)	11 (11.3)	5 (5.8)	12 (12.8)	1 (3.4)	17 (7.3)	χ² (4) = 5.369; P = 0.252, V = 0.100
Any 1 of 3 EPA criteria: n (%)	7 (7.2)	2 (2.3)	6 (6.4)	0	9 (3.9)	χ² (4) = 5.022; P = 0.285, V = 0.097
No CHR criterion: n (%)	86 (88.7)	81 (94.2)1	82 (87.2)	28 (96.6)	216 (92.7)	χ² (28) = 20.675; P = 0.839, V = 0.098
Only genetic risk and functional decline: n (%)	0	1 (1.2)	1 (1.1)	0	0
Only COPER: n (%)	4 (4.1)	2 (2.3)	5 (5.3)	1 (3.4)	8 (3.4) 1
Only COGDIS: n (%)	0	1 (1.2) 1	1 (1.1)	0	2 (0.9)
COPER and COGDIS: n (%)	3 (3.1)	1 (1.2)	2 (2.1)	0	2 (0.9)
Only APS: n (%)	2 (2.1)	0	2 (2.1)	0	5 (2.1)
APS and COPER: n (%)	1 (1.0)	0	0	0	0
APS, COPER and COGDIS: n (%)	1 (1.0)	0	1 (1.1)1	0	0

¹Indicates that 1 subject of this category converted to psychosis within 2 years. No brief intermittent psychotic symptoms (BIPS) criteria met. ED: Eating disorder; ADHD: attention-deficit hyperactivity disorder; AnxD and OCD: anxiety disorder, including obsessive-compulsive disorder; ASS: Asperger’s syndrome; APS: attenuated psychotic symptoms; COGDIS: Cognitive Disturbances; COPER: Cognitive-Perceptive Basic Symptoms: EPA: European Psychiatric Association; CHR: Clinical high-risk. V: Cramer’s V: 0.1 = weak effect; 0.3 = moderate effect; 0.5 = strong effect.